157 related articles for article (PubMed ID: 38034633)
1. Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment.
Chang FL; Tsai KC; Lin TY; Chiang CW; Pan SL; Lee YC
Heliyon; 2023 Nov; 9(11):e21774. PubMed ID: 38034633
[TBL] [Abstract][Full Text] [Related]
2. An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment.
Chang FL; Lee CC; Tsai KC; Lin TY; Chiang CW; Pan SL; Lee YC
Biochem Biophys Res Commun; 2023 Dec; 688():149214. PubMed ID: 37951154
[TBL] [Abstract][Full Text] [Related]
3. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
4. Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.
Ansuini H; Meola A; Gunes Z; Paradisi V; Pezzanera M; Acali S; Santini C; Luzzago A; Mori F; Lazzaro D; Ciliberto G; Nicosia A; La Monica N; Vitelli A
J Oncol; 2009; 2009():951917. PubMed ID: 20130824
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
[No Abstract] [Full Text] [Related]
6. Erythropoietin-Producing Hepatoma Receptor Tyrosine Kinase A2 Modulation Associates with Protective Effect of Prone Position in Ventilator-induced Lung Injury.
Park BH; Shin MH; Douglas IS; Chung KS; Song JH; Kim SY; Kim EY; Jung JY; Kang YA; Chang J; Kim YS; Park MS
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):519-529. PubMed ID: 29216437
[TBL] [Abstract][Full Text] [Related]
7. Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer.
Koshikawa N; Minegishi T; Kiyokawa H; Seiki M
Cell Death Dis; 2017 Oct; 8(10):e3134. PubMed ID: 29072678
[TBL] [Abstract][Full Text] [Related]
8. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
9. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
10. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
11. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.
Youngblood VM; Kim LC; Edwards DN; Hwang Y; Santapuram PR; Stirdivant SM; Lu P; Ye F; Brantley-Sieders DM; Chen J
Cancer Res; 2016 Apr; 76(7):1825-36. PubMed ID: 26833123
[TBL] [Abstract][Full Text] [Related]
12. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
13. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
14. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
15. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
16. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
Psilopatis I; Karniadakis I; Danos KS; Vrettou K; Michaelidou K; Mavridis K; Agelaki S; Theocharis S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613532
[TBL] [Abstract][Full Text] [Related]
17. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
18. The EphA2 and cancer connection: potential for immune-based interventions.
London M; Gallo E
Mol Biol Rep; 2020 Oct; 47(10):8037-8048. PubMed ID: 32990903
[TBL] [Abstract][Full Text] [Related]
19. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.
Yang XY; Zhu WJ; Jiang H
Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
Lee HY; Mohammed KA; Kaye F; Sharma P; Moudgil BM; Clapp WL; Nasreen N
Int J Nanomedicine; 2013; 8():4481-94. PubMed ID: 24293999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
